Call Start: 16:30 January 1, 0000 5:24 PM ET

REGENXBIO Inc. (NASDAQ:RGNX)
Q3 2024 Earnings Call
November 6, 2024 16:30 ET

Company Participants

Patrick Christmas - Chief Legal Officer
Curran Simpson - President and Chief Executive Officer
Mitchell Chan - Chief Financial Officer
Steve Pakola - Chief Medical Officer

Conference Call Participants

Gospel Enyindah-Asonye - Morgan Stanley
Mani Foroohar - Leerink Partners
Jack Padovano - Stifel
Luca Issi - RBC Capital Markets
Paul Choi - Goldman Sachs
Daniil Gataulin - Chardan
Yi Chen - H.C. Wainwright & Company

Operator

Welcome everyone to the Q3 2024 REGENXBIO Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. At this time, I’d like to turn the conference over to Patrick Christmas, Chief Legal Officer of REGENXBIO. Please go ahead.

Patrick Christmas

Good afternoon and thank you for joining us today. Earlier this afternoon, REGENXBIO released financial and operating results for the third quarter ended September 30, 2024. The press release is available on our website at www.regenxbio.com. Today’s conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend and other words of similar meaning.

Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the risk factors and the management’s discussion and analysis section of REGENXBIO’s annual report on Form 10-K for the full year ended December 31, 2023, and comparable Risk Factors sections of REGENXBIO’s quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available on the SEC’s website.

Any information we provide on this conference call is provided only as of the date of this call, November 6, 2024, and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise. Please be advised that today’s call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not report to project financial positions or operating results of the company. Actual results may differ materially.

I will now turn the call over to Curran Simpson, President and CEO of REGENXBIO.